title: Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study.
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Hotta
authors.forename: Akira
authors.initials: A
authors.lastname: Inoue
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Kiura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ueoka
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Nukiwa
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000503:physiopathology; D000075202:Contraindications; D003556:Cystitis / Q000139:chemically induced / Q000453:epidemiology; D005240:Feasibility Studies; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000453:epidemiology; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000139:chemically induced / Q000453:epidemiology; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib